VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+9.34%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$612M
AUM Growth
+$115M
(+23%)
Cap. Flow
+$92.1M
Cap. Flow
% of AUM
15.06%
Top 10 Holdings %
Top 10 Hldgs %
8.98%
Holding
532
New
97
Increased
238
Reduced
88
Closed
80
Top Buys
| 1 |
Telecom Argentina
TEO
|
$2.3M |
| 2 |
Methanex
MEOH
|
$1.47M |
| 3 |
The GEO Group
GEO
|
$1.43M |
| 4 |
EQM
EQM Midstream Partners, LP
EQM
|
$1.42M |
| 5 |
Vale
VALE
|
$1.35M |
Top Sells
| 1 |
Oxford Square Capital
OXSQ
|
$2.69M |
| 2 |
MPLX
MPLX
|
$1.51M |
| 3 |
MDCO
Medicines Co
MDCO
|
$982K |
| 4 |
Gladstone Investment Corp
GAIN
|
$839K |
| 5 |
CELG
Celgene Corp
CELG
|
$712K |
Sector Composition
| 1 | Financials | 20.46% |
| 2 | Real Estate | 16.88% |
| 3 | Energy | 14.34% |
| 4 | Healthcare | 10.85% |
| 5 | Materials | 9.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
GTHX
226
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $441K | 0.07% |
16,684
+3,081
| +23% | +$81.4K |
|
227
Atara Biotherapeutics
ATRA
$90.7M
| $439K | 0.07% |
1,067
+605
| +131% | +$249K |
|
|
AGEN
228
Agenus
AGEN
$138M
| $437K | 0.07% |
5,466
+627
| +13% | +$50.1K |
|
229
Iovance Biotherapeutics
IOVA
$901M
| $436K | 0.07% |
15,764
+2,539
| +19% | +$70.2K |
|
230
Akero Therapeutics
AKRO
$3.58B
| $433K | 0.07% |
+19,531
| New | +$433K |
|
231
Moderna
MRNA
$9.78B
| $433K | 0.07% |
22,133
+5,736
| +35% | +$112K |
|
|
ATNX
232
DELISTED
Athenex, Inc. Common Stock
ATNX
| $432K | 0.07% |
1,416
+706
| +99% | +$215K |
|
|
AUTL
233
Autolus Therapeutics
AUTL
$389M
| $430K | 0.07% |
32,577
+16,179
| +99% | +$214K |
|
234
Fate Therapeutics
FATE
$116M
| $429K | 0.07% |
21,917
+7,741
| +55% | +$152K |
|
235
Rocket Pharmaceuticals
RCKT
$354M
| $428K | 0.07% |
18,806
+3,143
| +20% | +$71.5K |
|
|
BHVN
236
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $428K | 0.07% |
7,860
+3,834
| +95% | +$209K |
|
237
Voyager Therapeutics
VYGR
$235M
| $427K | 0.07% |
30,608
+20,178
| +193% | +$281K |
|
238
AnaptysBio
ANAB
$613M
| $426K | 0.07% |
26,186
+22,566
| +623% | +$367K |
|
|
MYOV
239
DELISTED
Myovant Sciences Ltd.
MYOV
| $425K | 0.07% |
27,369
-1,811
| -6% | -$28.1K |
|
240
MacroGenics
MGNX
$126M
| $423K | 0.07% |
38,905
+22,311
| +134% | +$243K |
|
|
IMMU
241
DELISTED
Immunomedics Inc
IMMU
| $422K | 0.07% |
19,925
-523
| -3% | -$11.1K |
|
|
PGNX
242
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $419K | 0.07% |
82,233
+20,460
| +33% | +$104K |
|
243
Viking Therapeutics
VKTX
$3.03B
| $416K | 0.07% |
51,823
+19,672
| +61% | +$158K |
|
244
Q32 Bio
QTTB
$20.4M
| $412K | 0.07% |
+1,106
| New | +$412K |
|
245
Cytokinetics
CYTK
$6.34B
| $410K | 0.07% |
38,686
+12,199
| +46% | +$129K |
|
|
RARX
246
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $410K | 0.07% |
8,735
-3,146
| -26% | -$148K |
|
247
Akebia Therapeutics
AKBA
$785M
| $407K | 0.07% |
64,476
+2,846
| +5% | +$18K |
|
|
RETA
248
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $407K | 0.07% |
1,992
-1,109
| -36% | -$227K |
|
249
Y-mAbs Therapeutics
YMAB
$390M
| $406K | 0.07% |
+13,003
| New | +$406K |
|
250
Sangamo Therapeutics
SGMO
$165M
| $405K | 0.07% |
48,408
+21,277
| +78% | +$178K |
|